ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock News

Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews

An Overview of Adaptimmune Therapeutics's Earnings

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: NYSE APRE ACST AEMD ...

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: VNRX APRE CHRO PLX ...

ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adaptimmune Therapeutics (NASDAQ:ADAP) just reported results for the second qua...

ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024

ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

3 Biotech Moonshots With Imminent Catalyst Potential

Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.

Mentions: VKTX GH

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning!

Mentions: XHG LPA BURU NVOS ...

ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024

ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.